{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:32:50Z","timestamp":1792171970811,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40291-022-00638-7","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T21:44:48Z","timestamp":1674510288000},"page":"371-381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical Evaluation of IDH Mutation Status in Formalin-Fixed Paraffin-Embedded Tissue in Gliomas"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8598-5395","authenticated-orcid":false,"given":"Ernest J.","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Gubbiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia M.","family":"Carlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4861-0898","authenticated-orcid":false,"given":"MacLean P.","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7400-9097","authenticated-orcid":false,"given":"Vivianna M.","family":"Van Deerlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1457-211X","authenticated-orcid":false,"given":"Sarah E.","family":"Herlihy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"issue":"9","key":"638_CR1","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1001\/jamaoncol.2018.1789","volume":"4","author":"QT Ostrom","year":"2018","unstructured":"Ostrom QT, Cote DJ, Ascha M, Kruchko C, et al. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol. 2018;4(9):1254\u201362.","journal-title":"JAMA Oncol"},{"issue":"11","key":"638_CR2","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1093\/neuonc\/nox091","volume":"19","author":"R Leece","year":"2017","unstructured":"Leece R, Xu J, Ostrom QT, et al. Global incidence of malignant brain and other central nervous system tumors by histology, 2003\u20132007. Neuro Oncol. 2017;19(11):1553\u201364.","journal-title":"Neuro Oncol"},{"key":"638_CR3","unstructured":"World Health Organization. Central nervous system tumours. WHO classification of tumours. 5th edn. vol. 6. 2021. https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Who-Classification-Of-Tumours\/Central-Nervous-System-Tumours-2021.."},{"issue":"4","key":"638_CR4","first-page":"5405","volume":"16","author":"L Deng","year":"2018","unstructured":"Deng L, Xiong P, Luo Y, et al. Association between IDH1\/2 mutations and brain glioma grade. Oncol Lett. 2018;16(4):5405\u20139.","journal-title":"Oncol Lett"},{"issue":"5","key":"638_CR5","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMra0708126","volume":"359","author":"PY Wen","year":"2008","unstructured":"Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492\u2013507.","journal-title":"N Engl J Med"},{"issue":"10","key":"638_CR6","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"issue":"9","key":"638_CR7","first-page":"2613","volume":"19","author":"S Witthayanuwat","year":"2018","unstructured":"Witthayanuwat S, Pesee M, Supaadirek C, et al. Survival analysis of glioblastoma multiforme. Asian Pac J Cancer Prev. 2018;19(9):2613\u20137.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"10","key":"638_CR8","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.3390\/cancers11101616","volume":"11","author":"JW Park","year":"2019","unstructured":"Park JW, Turcan S. Epigenetic reprogramming for targeting IDH-mutant malignant gliomas. Cancers (Basel). 2019;11(10):1616.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"638_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1349-7006.2011.02134.x","volume":"103","author":"Q SongTao","year":"2012","unstructured":"SongTao Q, Lei Y, Si G, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci. 2012;103(2):269\u201373.","journal-title":"Cancer Sci"},{"issue":"7","key":"638_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068782","volume":"8","author":"P Zou","year":"2013","unstructured":"Zou P, Xu H, Chen P, et al. IDH1\/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS One. 2013;8(7):e68782.","journal-title":"PLoS One"},{"issue":"4","key":"638_CR11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/annonc\/mdw013","volume":"27","author":"L Dang","year":"2016","unstructured":"Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol. 2016;27(4):599\u2013608.","journal-title":"Ann Oncol"},{"key":"638_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.651317","volume":"9","author":"X Du","year":"2021","unstructured":"Du X, Hu H. The roles of 2-hydroxyglutarate. Front Cell Dev Biol. 2021;9:651317.","journal-title":"Front Cell Dev Biol."},{"issue":"10","key":"638_CR13","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.tcb.2017.06.002","volume":"27","author":"LM Gagn\u00e9","year":"2017","unstructured":"Gagn\u00e9 LM, Boulay K, Topisirovic I, et al. Oncogenic activities of IDH1\/2 mutations: from epigenetics to cellular signaling. Trends Cell Biol. 2017;27(10):738\u201352.","journal-title":"Trends Cell Biol"},{"issue":"5","key":"638_CR14","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/ng.3273","volume":"47","author":"H Suzuki","year":"2015","unstructured":"Suzuki H, Aoki K, Chiba K, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015;47(5):458\u201368.","journal-title":"Nat Genet"},{"issue":"117","key":"638_CR15","first-page":"373","volume":"21","author":"T Fujii","year":"2016","unstructured":"Fujii T, Khawaja MR, DiNardo CD, et al. Targeting isocitrate dehydrogenase (IDH) in cancer. Discov Med. 2016;21(117):373\u201380.","journal-title":"Discov Med"},{"issue":"5897","key":"638_CR16","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807\u201312.","journal-title":"Science"},{"issue":"8","key":"638_CR17","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1101\/gad.217406.113","volume":"27","author":"JA Losman","year":"2013","unstructured":"Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013;27(8):836\u201352.","journal-title":"Genes Dev"},{"issue":"6","key":"638_CR18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00401-008-0455-2","volume":"116","author":"J Balss","year":"2008","unstructured":"Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116(6):597\u2013602.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"638_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/humu.20937","volume":"30","author":"FE Bleeker","year":"2009","unstructured":"Bleeker FE, Lamba S, Leenstra S, et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat. 2009;30(1):7\u201311.","journal-title":"Hum Mutat"},{"key":"638_CR20","doi-asserted-by":"publisher","unstructured":"Chang C, Xu K, Shu HG. The role of isocitrate dehydrogenase mutations in glioma brain tumors. Molecular Targets of CNS Tumors. In: InTechOpen; 2011. https:\/\/doi.org\/10.5772\/23238.","DOI":"10.5772\/23238"},{"issue":"5","key":"638_CR21","first-page":"816","volume":"67","author":"I Khan","year":"2017","unstructured":"Khan I, Waqas M, Shamim MS. Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme. J Pak Med Assoc. 2017;67(5):816\u20137.","journal-title":"J Pak Med Assoc"},{"issue":"4","key":"638_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00401-010-0645-6","volume":"119","author":"FE Bleeker","year":"2010","unstructured":"Bleeker FE, Atai NA, Lamba S, et al. The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010;119(4):487\u201394.","journal-title":"Acta Neuropathol"},{"issue":"19","key":"638_CR23","doi-asserted-by":"publisher","first-page":"10373","DOI":"10.3390\/ijms221910373","volume":"22","author":"P Sledzinska","year":"2021","unstructured":"Sledzinska P, Bebyn MG, Furtak J. Prognostic and predictive biomarkers in gliomas. Int J Mol Sci. 2021;22(19):10373.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"638_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1215\/15228517-2009-025","volume":"11","author":"K Ichimura","year":"2009","unstructured":"Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009;11(4):341\u20137.","journal-title":"Neuro Oncol"},{"issue":"1","key":"638_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40291-013-0050-7","volume":"18","author":"M Lewandowska","year":"2014","unstructured":"Lewandowska M, Furtak J, Szylberg T, et al. An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients. Mol Diagnosis Ther. 2014;18(1):45\u201353.","journal-title":"Mol Diagnosis Ther."},{"issue":"3","key":"638_CR26","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s12035-015-9104-7","volume":"53","author":"YT Dai","year":"2016","unstructured":"Dai YT, Ning XB, Han GQ, et al. Assessment of the association between isocitrate dehydrogenase 1 mutation and mortality risk of glioblastoma patients. Mol Neurobiol. 2016;53(3):1501\u20138.","journal-title":"Mol Neurobiol"},{"issue":"9","key":"638_CR27","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/neuonc\/nou005","volume":"16","author":"RJ Molenaar","year":"2014","unstructured":"Molenaar RJ, Verbaan D, Lamba S, et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol. 2014;16(9):1263\u201373.","journal-title":"Neuro Oncol"},{"issue":"17","key":"638_CR28","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1212\/WNL.0b013e3181f96282","volume":"75","author":"C Houillier","year":"2010","unstructured":"Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010;75(17):1560\u20136.","journal-title":"Neurology"},{"issue":"6","key":"638_CR29","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2174\/1568026618666180518091144","volume":"l8","author":"H Sharma","year":"2018","unstructured":"Sharma H. Development of novel therapeutics targeting isocitrate dehydrogenase mutations in cancer. Curr Top Med Chem. 2018;l8(6):505\u201324.","journal-title":"Curr Top Med Chem"},{"issue":"29","key":"638_CR30","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1200\/JCO.19.03327","volume":"38","author":"IK Mellinghoff","year":"2020","unstructured":"Mellinghoff IK, Ellingson BM, Touat M, et al. Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. J Clin Oncol. 2020;38(29):3398\u2013406.","journal-title":"J Clin Oncol"},{"issue":"12","key":"638_CR31","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1093\/neuonc\/nox120","volume":"19","author":"JC DeWitt","year":"2017","unstructured":"DeWitt JC, Jordan JT, Frosch MP, et al. Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations. Neuro Oncol. 2017;19(12):1640\u201350.","journal-title":"Neuro Oncol"},{"key":"638_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/2051-5960-2-58","volume":"2","author":"A Catteau","year":"2014","unstructured":"Catteau A, Girardi H, Monville F, et al. A new sensitive PCR assay for one-step detection of 12 IDH1\/2 mutations in glioma. Acta Neuropathol Commun. 2014;2:58.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"638_CR33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s40478-018-0633-y","volume":"6","author":"NE Synhaeve","year":"2018","unstructured":"Synhaeve NE, van den Bent MJ, French PJ, et al. Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics. Acta Neuropathol Commun. 2018;6(1):126.","journal-title":"Acta Neuropathol Commun"},{"key":"638_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cancergen.2018.08.004","volume":"228\u2013229","author":"RT Sussman","year":"2018","unstructured":"Sussman RT, Shaffer S, Azzato EM, et al. Validation of a next-generation sequencing oncology panel optimized for low input DNA. Cancer Genet. 2018;228\u2013229:55\u201363.","journal-title":"Cancer Genet"},{"issue":"10","key":"638_CR35","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1097\/PAI.0000000000000702","volume":"27","author":"DD Gondim","year":"2019","unstructured":"Gondim DD, Gener MA, Curless KL, et al. Determining IDH-mutational status in gliomas using IDH1-R132H antibody and polymerase chain reaction. Appl Immunohistochem Mol Morphol. 2019;27(10):722\u20135.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"3","key":"638_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/BF03256369","volume":"14","author":"M Bujko","year":"2010","unstructured":"Bujko M, Kober P, Matyja E, et al. Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients. Mol Diagn Ther. 2010;14(3):163\u20139.","journal-title":"Mol Diagn Ther"},{"issue":"4","key":"638_CR37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2353\/jmoldx.2010.090228","volume":"12","author":"C Horbinski","year":"2010","unstructured":"Horbinski C, Kelly L, Nikiforov YE, et al. Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J Mol Diagn. 2010;12(4):487\u201392.","journal-title":"J Mol Diagn"},{"issue":"5","key":"638_CR38","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1750-3639.2012.00579.x","volume":"22","author":"M Perizzolo","year":"2012","unstructured":"Perizzolo M, Winkfein B, Hui S, et al. IDH mutation detection in formalin-fixed paraffin-embedded gliomas using multiplex PCR and single-base extension. Brain Pathol. 2012;22(5):619\u201324.","journal-title":"Brain Pathol"},{"issue":"3","key":"638_CR39","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s12253-018-0413-9","volume":"25","author":"I Urbanovska","year":"2019","unstructured":"Urbanovska I, Megova MH, Dwight Z, et al. IDH mutation analysis in glioma patients by CADMA compared with SNaPshot assay and two immunohistochemical methods. Pathol Oncol Res. 2019;25(3):971\u20138.","journal-title":"Pathol Oncol Res"},{"issue":"4","key":"638_CR40","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00401-010-0647-4","volume":"119","author":"J Felsberg","year":"2010","unstructured":"Felsberg J, Wolter M, Seul H, et al. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol. 2010;119(4):501\u20137.","journal-title":"Acta Neuropathol"},{"issue":"11","key":"638_CR41","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.31557\/APJCP.2020.21.11.3229","volume":"21","author":"RG Malueka","year":"2020","unstructured":"Malueka RG, Theresia E, Fitria F, et al. Comparison of polymerase chain reaction-restriction fragment length polymorphism, immunohistochemistry, and DNA sequencing for the detection of IDH1 mutations in gliomas. Asian Pac J Cancer Prev. 2020;21(11):3229\u201334.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"6","key":"638_CR42","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/neuonc\/not015","volume":"15","author":"S Agarwal","year":"2013","unstructured":"Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Neuro Oncol. 2013;15(6):718\u201326.","journal-title":"Neuro Oncol"},{"issue":"3","key":"638_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/bpa.12000","volume":"23","author":"D Lee","year":"2013","unstructured":"Lee D, Suh YL, Kang SY, et al. IDH1 mutations in oligodendroglial tumors: comparative analysis of direct sequencing, pyrosequencing, immunohistochemistry, nested PCR and PNA-mediated clamping PCR. Brain Pathol. 2013;23(3):285\u201393.","journal-title":"Brain Pathol"},{"issue":"8","key":"638_CR44","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/NEN.0b013e31822713f0","volume":"70","author":"M Preusser","year":"2011","unstructured":"Preusser M, Wohrer A, Stary S, et al. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol. 2011;70(8):715\u201323.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"7","key":"638_CR45","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/nrclinonc.2016.204","volume":"14","author":"G Reifenberger","year":"2017","unstructured":"Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, et al. Advances in the molecular genetics of gliomas: implications for classification and therapy. Nat Rev Clin Oncol. 2017;14(7):434\u201352.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"638_CR46","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/neuonc\/noy201","volume":"21","author":"TA Bale","year":"2019","unstructured":"Bale TA, Jordan JT, Rapalino O, et al. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Neuro Oncol. 2019;21(5):596\u2013605.","journal-title":"Neuro Oncol"},{"issue":"10","key":"638_CR47","doi-asserted-by":"publisher","first-page":"7900","DOI":"10.3390\/curroncol29100624","volume":"29","author":"N Banyi","year":"2022","unstructured":"Banyi N, Alex D, Hughesman C, et al. Improving time-to-treatment for advanced non-small cell lung cancer patients through faster single gene EGFR testing using the Idylla EGFR testing platform. Curr Oncol. 2022;29(10):7900\u201311.","journal-title":"Curr Oncol"},{"issue":"10","key":"638_CR48","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa2024534","volume":"384","author":"EJ Duncavage","year":"2021","unstructured":"Duncavage EJ, Schroeder MC, O'Laughlin M, et al. Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers. N Engl J Med. 2021;384(10):924\u201335.","journal-title":"N Engl J Med"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-022-00638-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-022-00638-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-022-00638-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:12:15Z","timestamp":1744715535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-022-00638-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["638"],"URL":"https:\/\/doi.org\/10.1007\/s40291-022-00638-7","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]},"assertion":[{"value":"18 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Abbott Molecular Inc. sponsored Sarah E. Herlihy for a Lab Roots lecture of the validation data presented in this article. All data validation and analysis were completed prior to the service initiation. Ernest J. Nelson, Maria A. Gubbiotti, Alicia M. Carlin, MacLean P. Nasrallah, Vivianna M. Van Deerlin have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data generated or analyzed during this study are included in this article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: EJN, MPN, SEH; methodology: EJN, AMC, SEH; formal analysis and investigation: EJN, MAG, AMC, VMVD, SEH; writing, original draft preparation: EJN, SEH; writing, review and editing: EJN, MAG, AMC, MPN, VMVD, SEH; supervision: MPN, VMVD, SEH.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}